Liu Chang-Cheng, Ye Jinfeng, Cao Hongzhi
National Glycoengineering Research Center, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, and Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Key Laboratory of Marine Drugs of Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Acc Chem Res. 2024 Jan 29. doi: 10.1021/acs.accounts.3c00754.
ConspectusThe limited availability of structurally well-defined diverse glycans remains a major obstacle for deciphering biological functions as well as biomedical applications of carbohydrates. Despite tremendous progress that has been made in past decades, the synthesis of structurally well-defined complex glycans still represents one of the most challenging topics in synthetic chemistry. Chemical synthesis of glycans is a time-consuming and labor-intensive process that requires elaborate planning and skilled personnel. In contrast, glycosyltransferase-catalyzed enzymatic synthesis provides a more efficient, convenient, low-cost, and sustainable alternative to affording diverse and complex glycans. However, the existing methods are still insufficient to fulfill the increasing demand for specific synthetic glycan libraries necessary for functional glycomics research. This is mainly attributed to the inherent character of the glycan biosynthetic pathway. In nature, there are too many glycosyltransferases involved in the glycan synthesis, but only a small number of them are available for enzymatic synthesis. For instance, humans have over 200 glycosyltransferases, but only a few of them could be produced from the conventional bacterial expression system, and most of these membrane-associated enzymes could be overexpressed only in eukaryotic cells. Moreover, the glycan biosynthetic pathway is a nontemplate-driven process, which eventually ends up with heterogeneous glycan product mixtures. Therefore, it is not a practical solution for the enzymatic synthesis of complex glycans by simply copying the glycan biosynthetic pathway.In the past decade, we have tried to develop a simplified and transformable approach to the enzymatic modular assembly of a human glycan library. Despite the structural complexity of human glycans, the glycoinformatic analysis based on the known glycan structure database and the human glycosyltransferase database indicates that there are approximately 56 disaccharide patterns present in the human glycome and only 16 disaccharide linkages are required to account for over 80% of the total disaccharide fragments, while 35 disaccharide linkages are sufficient to cover over 95% of all disaccharide fragments of human glycome. Regardless of the substrate specificity, if one glycosyltransferase could be used for the synthesis of all of the same glycosidic linkages in human glycome, it will require only a few dozen glycosyltransferases for the assembly of entire human glycans. According to the glycobioinformatics analysis results, we rationally designed about two dozen enzyme modules for the synthesis of over 20 common glycosidic linkages in human glycome, in which each enzyme module contains a glycosyltransferase and a group of enzymes for the generation of a nucleotide-activated sugar donor. By sequential glycosylation using orchestrated enzyme modules, we have completed the synthesis of over 200 structurally well-defined complex human glycans including blood group antigens, -mannosyl glycans, human milk oligosaccharides, and others. To overcome the product microheterogeneity problem of enzymatic synthesis in the nontemplate-driven glycan biosynthetic pathway, we developed several substrate engineering strategies to control or manipulate the outcome of glycosyltransferase-catalyzed reactions for the precise synthesis of structurally well-defined isomeric complex glycans.
概述
结构明确的多样化聚糖的有限可得性仍然是解析碳水化合物的生物学功能以及生物医学应用的主要障碍。尽管在过去几十年中取得了巨大进展,但结构明确的复杂聚糖的合成仍然是合成化学中最具挑战性的课题之一。聚糖的化学合成是一个耗时且费力的过程,需要精心规划和熟练的人员。相比之下,糖基转移酶催化的酶促合成提供了一种更高效、便捷、低成本且可持续的替代方法,可用于生成多样化和复杂的聚糖。然而,现有方法仍不足以满足功能糖组学研究对特定合成聚糖文库日益增长的需求。这主要归因于聚糖生物合成途径的固有特性。在自然界中,聚糖合成涉及太多糖基转移酶,但其中只有少数可用于酶促合成。例如,人类有超过200种糖基转移酶,但只有少数几种可以从传统细菌表达系统中产生,而且这些膜相关酶中的大多数只能在真核细胞中过量表达。此外,聚糖生物合成途径是一个非模板驱动的过程,最终会产生异质聚糖产物混合物。因此,简单复制聚糖生物合成途径来进行复杂聚糖的酶促合成并不是一个实际可行的解决方案。
在过去十年中,我们试图开发一种简化且可转化的方法来进行人类聚糖文库的酶促模块化组装。尽管人类聚糖结构复杂,但基于已知聚糖结构数据库和人类糖基转移酶数据库的糖组信息分析表明,人类糖组中大约存在56种二糖模式,仅需16种二糖连接就能涵盖超过80%的二糖片段总数,而35种二糖连接足以覆盖人类糖组所有二糖片段的95%以上。无论底物特异性如何,如果一种糖基转移酶可用于合成人类糖组中所有相同的糖苷键,那么组装整个人类聚糖仅需要几十种糖基转移酶。根据糖组生物信息学分析结果,我们合理设计了大约二十几种酶模块,用于合成人类糖组中20多种常见的糖苷键,其中每个酶模块包含一种糖基转移酶和一组用于生成核苷酸活化糖供体的酶。通过使用精心编排的酶模块进行顺序糖基化,我们已经完成了200多种结构明确的复杂人类聚糖的合成,包括血型抗原、α-甘露糖基聚糖、人乳寡糖等。为了克服非模板驱动的聚糖生物合成途径中酶促合成的产物微异质性问题,我们开发了几种底物工程策略,以控制或操纵糖基转移酶催化反应的结果,从而精确合成结构明确的异构复杂聚糖。